Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology

04-01-2025 | Retroperitoneal Fibrosis | ORIGINAL ARTICLE

Clinical characteristics of IgG4-related retroperitoneal fibrosis in a cohort of 117 patients with idiopathic retroperitoneal fibrosis: a retrospective study

Authors: Jia-Qi Hu, Zheng-Yi Jin, Yi-Yi Yu, Du-Mu Min, Qing Cai, Jie Gao

Published in: Clinical Rheumatology

Login to get access

Abstract

Objective

Retroperitoneal fibrosis (RPF) is a rare condition marked by inflammation and fibrosis affecting the peritoneal and retroperitoneal soft tissues. In recent years, the identification of IgG4-related diseases has brought to light a significant association with fibrous disorders, including RPF, which were once considered independent. In this comprehensive cohort study, we performed a comparative analysis of the demographic, clinical, laboratory, histopathological, and therapeutic characteristics between patients with IgG4-related RPF and those with idiopathic retroperitoneal fibrosis (iRPF).

Methods

We performed a retrospective analysis of 117 patients diagnosed with RPF at the First Affiliated Hospital of Naval Medical University between July 2007 and July 2023.

Results

Demographic, clinical, laboratory, histopathological, and therapeutic characteristics of 70 iRPF patients and 47 IgG4-related patients were systematically compared. The IgG4-related group exhibited an older age of onset, with a predominant occurrence among adult males. Significantly elevated levels of eosinophilia and IgE were observed in the IgG4-related group. Most patients across both groups displayed elevated CRP and ESR levels. Furthermore, at the time of diagnosis, the IgG4-related group had higher serum creatinine and lower levels of complement. The most prevalent clinical manifestation in both groups was flank pain. The proportion of lymphoplasmic infiltration and storiform fibrosis in IgG4-related RPF group was significantly higher. The IgG4-related RPF group had significantly higher IgG4-positive plasma cell count, IgG4/total IgG ratio, and eosinophils count than that in iRPF group.

Conclusion

We conducted a comparative analysis of demographic, clinical, laboratory, histopathological, and therapeutic differences between the iRPF patients and the IgG4-related patients. Clarifying the distinctive characteristics of these two groups will contribute to a better understanding of the condition and facilitate the development of specific treatment strategies tailored to each group.
Key Points
• Identification of distinct clinical features and outcomes between IgG4-related and iRPF patients in a large retrospective study.
Literature
1.
Vaglio A, Salvarani C, Buzio C (2006) Retroperitoneal fibrosis. The Lancet 367(9506):241–251CrossRef
2.
Arrive L, Correas JM, Leseche G et al (1995) Inflammatory aneurysms of the abdominal aorta: CT findings. AJR Am J Roentgenol 165(6):1481–1484PubMedCrossRef
3.
Warnatz K, Keskin AG, Uhl M et al (2005) Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 64(6):828–833PubMedPubMedCentralCrossRef
4.
Khosroshahi A, Carruthers MN, Stone JH et al (2013) Rethinking Ormond’s disease:“idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Medicine 92(2):82–91PubMedPubMedCentralCrossRef
5.
Vaglio A, Greco P, Corradi D et al (2006) Autoimmune aspects of chronic periaortitis. Autoimmun Rev 5(7):458–464PubMedCrossRef
6.
Liu Y, Zhu L, Wang Z et al (2021) Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study. Rheumatology 60(2):767–772PubMedCrossRef
7.
Van Bommel EFH, Jansen I, Hendriksz TR et al (2009) Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine 88(4):193–201PubMedCrossRef
8.
Kamisawa T, Zen Y, Pillai S et al (2015) IgG4-related disease. The Lancet 385(9976):1460–1471CrossRef
9.
10.
Umehara H, Okazaki K, Masaki Y et al (2012) A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 22(1):1–14PubMedCrossRef
11.
12.
Hamano H, Kawa S, Horiuchi A et al (2001) High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344(10):732–738PubMedCrossRef
13.
Maritati F, Peyronel F, Vaglio A (2020) IgG4-related disease: a clinical perspective. Rheumatology (Oxford) 59(Supplement_3):iii123–iii131PubMedCrossRef
14.
Chaba A, Devresse A, Audard V et al (2023) Clinical and prognostic factors in patients with IgG4-related kidney disease. Clin J Am Soc Nephrol 18(8):1031–1040PubMedPubMedCentral
15.
Zhang X, Jin X, Guan L et al (2022) IgG4-related disease with gastrointestinal involvement: case reports and literature review. Front Immunol 13:816830PubMedPubMedCentralCrossRef
16.
Löhr JM, Vujasinovic M, Rosendahl J et al (2022) IgG4-related diseases of the digestive tract. Nat Rev Gastroenterol Hepatol 19(3):185–197PubMedCrossRef
17.
Demir AM, Aydin F, Acar B et al (2021) IgG4-related disease and ANCA positive vasculitis in childhood: a case-based review. Clin Rheumatol 40(9):3817–3825PubMedCrossRef
18.
AbdelRazek MA, Venna N, Stone JH (2018) IgG4-related disease of the central and peripheral nervous systems. The Lancet Neurology 17(2):183–192PubMedCrossRef
19.
Kanda M, Kamekura R, Sugawara M et al (2023) IgG4-related disease administered dupilumab: case series and review of the literature. RMD Open 9(1):e003026PubMedPubMedCentralCrossRef
20.
21.
Dragan AD, Weller A, Lingam RK (2021) Imaging of IgG4-related disease in the extracranial head and neck. Eur J Radiol 136:109560PubMedCrossRef
22.
Okamoto S, Tsuboi H, Sato R et al (2020) IgG4-related pleural disease with aortitis and submandibular glands involvement successfully treated with corticosteroid: case-based review. Rheumatol Int 40:1725–1732PubMedCrossRef
23.
Zen Y, Nakanuma Y (2010) IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 34(12):1812–1819PubMedCrossRef
24.
Deshpande V, Zen Y, Chan JKC et al (2012) Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25(9):1181–1192PubMedCrossRef
25.
Umehara H, Okazaki K, Kawa S et al (2021) The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31(3):529–533PubMedCrossRef
26.
27.
Lin W, Lu S, Chen H et al (2015) Clinical characteristics of immunoglobulin G4–related disease: a prospective study of 118 Chinese patients. Rheumatology 54(11):1982–1990PubMedCrossRef
28.
Wang L, Zhang P, Zhang X et al (2019) Sex disparities in clinical characteristics and prognosis of immunoglobulin G4–related disease: a prospective study of 403 patients. Rheumatology 58(5):820–830PubMedCrossRef
29.
Qing P, Lu C, Liu Z et al (2021) IgG4-related disease with tuberculosis: a case report and retrospective review of patients in a single center. Front Immunol 12:652985PubMedPubMedCentralCrossRef
30.
31.
Kermani TA, Crowson CS, Achenbach SJ et al (2011) Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes[C]//Mayo Clinic Proceedings. Elsevier 86(4):297–303
32.
Wang K, Wang Z, Zeng Q et al (2021) Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS ONE 16(2):e0245601PubMedPubMedCentralCrossRef
33.
Carruthers M, Augustin T, Stone J H, et al (2012) Diagnostic utility of serum IgG4 in IgG4-related disease[C]//Arthritis And Rheumatism. 111 River St, Hoboken 07030–5774, NJ USA: Wiley-Blackwell 64(10):S815-S816
34.
Puxeddu I, Capecchi R, Carta F et al (2018) Salivary gland pathology in IgG4-related disease: a comprehensive review. J Immunol Res 2018:1CrossRef
35.
Koo BS, Koh YW, Hong S et al (2015) Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Mod Rheumatol 25(2):194–198PubMedCrossRef
36.
Cheuk W, Yuen HKL, Chu SYY et al (2008) Lymphadenopathy of IgG4-related sclerosing disease. Am J Surg Pathol 32(5):671–681PubMedCrossRef
37.
Labidi J, Ariba YB, Chargui S et al (2015) Retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment and outcomes. Saudi J Kidney Dis Trans 26(4):816–822CrossRef
38.
Fernando A, Pattison J, Horsfield C et al (2017) 18F]-Fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study[J. Eur Urol 71(6):926–933PubMedCrossRef
39.
AccorsiButtini E, Maritati F, Vaglio A (2018) 18F]-Fluorodeoxyglucose positron emission tomography and response to therapy in idiopathic retroperitoneal fibrosis[J. Eur Urol 73:145–146CrossRef
40.
Perugino CA, Mattoo H, Mahajan VS et al (2017) Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies. Arthritis Rheumatol 69(9):1722–1732PubMedPubMedCentralCrossRef
41.
Mattoo H, Mahajan VS, Maehara T et al (2016) Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 138(3):825–838PubMedPubMedCentralCrossRef
42.
Akiyama M, Suzuki K, Yasuoka H et al (2018) Follicular helper T cells in the pathogenesis of IgG4-related disease. Rheumatology 57(2):236–245PubMedCrossRef
43.
van Bommel EFH, Siemes C, Hak LE et al (2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49(5):615–625PubMedCrossRef
44.
Binder M, Uhl M, Wiech T et al (2012) Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 71(2):311–312PubMedCrossRef
45.
Vaglio A, Catanoso MG, Spaggiari L et al (2013) Brief report: Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum 65(9):2469–2475PubMedCrossRef
46.
Urban ML, Maritati F, Palmisano A et al (2020) Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. Ann Rheum Dis 79(3):433–434PubMedCrossRef
47.
Scheel PJ, Feeley N (2013) Retroperitoneal fibrosis. Rheum Dis Clin 39(2):365–381CrossRef
48.
Lanzillotta M, Culver E, Sharma A et al (2024) Fibrotic phenotype of IgG4-related disease. Lancet Rheumatol 6:e469PubMedCrossRef
49.
Katz G, Hernandez-Barco Y, Palumbo D et al (2024) Proliferative features of IgG4-related disease. Lancet Rheumatol 6:e481PubMedCrossRef
50.
Cohan RH, Shampain KL, Francis IR et al (2018) Imaging appearance of fibrosing diseases of the retroperitoneum: can a definitive diagnosis be made? Abdom Radiol 43:1204–1214CrossRef
51.
Moroni G, Castellani M, Balzani A et al (2012) The value of 18 F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 39:1635–1642PubMedCrossRef
Metadata
Title
Clinical characteristics of IgG4-related retroperitoneal fibrosis in a cohort of 117 patients with idiopathic retroperitoneal fibrosis: a retrospective study
Authors
Jia-Qi Hu
Zheng-Yi Jin
Yi-Yi Yu
Du-Mu Min
Qing Cai
Jie Gao
Publication date
04-01-2025
Publisher
Springer International Publishing
Published in
Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-07276-w

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits